Open in Screener

ROIV

Roivant Sciences Ltd

Jan 28 • 11:20AM ET

22.07

-0.47 -2.06 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB VBK XBI VXF MDY IBB SPMD DFAS

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	37.10%	Shs Outstand	689.70M	Perf Week	-3.98%
Market Cap	15.35B	Forward P/E	-	EPS next Y	-1.26	Insider Trans	-8.36%	Shs Float	437.45M	Perf Month	-0.74%
Enterprise Value	11.50B	PEG	-	EPS next Q	-0.30	Inst Own	64.59%	Short Float	5.61%	Perf Quarter	17.30%
Income	-373.97M	P/S	754.85	EPS this Y	-365.48%	Inst Trans	2.19%	Short Ratio	3.27	Perf Half Y	93.21%
Sales	20.33M	P/B	3.49	EPS next Y	-13.14%	ROA	-12.44%	Short Interest	24.53M	Perf YTD	1.68%
Book/sh	6.32	P/C	3.50	EPS next 5Y	-25.94%	ROE	-14.73%	52W High	23.91 -7.72%	Perf Year	98.07%
Cash/sh	6.31	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-8.40%	52W Low	8.73 152.75%	Perf 3Y	159.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	70.12%	Volatility	2.76% 3.13%	Perf 5Y	112.98%
Dividend TTM	-	EV/Sales	565.66	EPS Y/Y TTM	-109.22%	Oper. Margin	-5659.41%	ATR (14)	0.72	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	33.70	Sales Y/Y TTM	-83.82%	Profit Margin	-1839.58%	RSI (14)	47.19	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	33.70	EPS Q/Q	46.74%	SMA20	-1.62%	Beta	1.23	Target Price	27.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-64.89%	SMA50	1.66%	Rel Volume	0.50	Prev Close	22.53
Employees	750	LT Debt/Eq	0.02	Earnings	Feb 06 BMO	SMA200	44.45%	Avg Volume	7.51M	Price	22.07
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.87% -72.04%	Trades		Volume	1,187,380	Change	-2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
02:00AM	Loading…
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
04:54PM	Loading…
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Loading…
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)
Jan-29-25 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 (GlobeNewswire)
Jan-15-25 08:49PM	Vivek Ramaswamy Open to Replacing JD Vance in Senateif Offered (The Wall Street Journal)
Jan-12-25 09:40AM	Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 03:28AM	Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing (Insider Monkey)
Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & Immunovant CEO	Jan 12 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Jan 14 09:00 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Sale	21.92	200,000	4,384,000	1,654,597	Jan 14 09:00 PM
Venker Eric	Officer	Jan 12 '26	Proposed Sale	21.92	200,000	4,383,694		Jan 12 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Option Exercise	12.68	2,449,877	31,064,440	21,286,424	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Option Exercise	12.68	748,358	9,489,179	19,584,905	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Sale	21.71	1,018,995	22,122,381	20,267,429	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Sale	21.74	311,873	6,780,119	19,273,032	Dec 31 09:00 PM
Sukhatme Mayukh	Officer	Dec 31 '25	Proposed Sale	21.71	1,018,995	22,119,828		Dec 31 04:30 PM
Pulik Richard	CFO	Dec 23 '25	Option Exercise	3.85	260,000	1,001,000	646,144	Dec 29 09:00 PM
Pulik Richard	CFO	Dec 23 '25	Sale	22.43	406,731	9,122,307	239,413	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Option Exercise	3.85	313,841	1,208,288	1,811,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Option Exercise	3.85	117,848	453,715	1,729,597	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Sale	22.45	200,000	4,490,000	1,611,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Sale	22.53	75,000	1,689,750	1,654,597	Dec 29 09:00 PM
Sukhatme Mayukh	Officer	Dec 29 '25	Proposed Sale	21.74	311,873	6,781,263		Dec 29 04:31 PM
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Sale	16.15	355,161	5,735,850	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Sale	16.34	171,396	2,800,611	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Sale	16.20	138,602	2,245,352	1,504,959	Oct 08 09:00 PM
Venker Eric	Officer	Oct 08 '25	Proposed Sale	16.20	138,602	2,244,797		Oct 08 04:15 PM
Venker Eric	Officer	Oct 07 '25	Proposed Sale	16.15	355,161	5,734,289		Oct 07 04:34 PM
Venker Eric	Officer	Oct 06 '25	Proposed Sale	16.34	171,396	2,800,365		Oct 06 04:46 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Option Exercise	3.85	1,000,000	3,850,000	2,653,585	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Option Exercise	3.85	562,374	2,165,140	2,532,141	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Sale	14.95	683,818	10,223,079	1,969,767	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 23 '25	Sale	14.83	611,000	9,061,130	1,504,959	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Sale	14.99	416,182	6,240,568	2,115,959	Sep 23 09:00 PM
Venker Eric	Officer	Sep 23 '25	Proposed Sale	14.94	611,079	9,129,520		Sep 23 09:45 AM
ERIC VENKER	Officer	Sep 22 '25	Proposed Sale	14.99	316,182	4,741,054		Sep 22 04:20 PM
Venker Eric	Officer	Sep 22 '25	Proposed Sale	15.01	100,000	1,501,339		Sep 22 04:07 PM
ERIC VENKER	Officer	Sep 19 '25	Proposed Sale	14.95	683,818	10,220,412		Sep 19 04:32 PM
Gline Matthew	CEO	Sep 18 '25	Buy	15.07	3,315	49,957	17,287,081	Sep 18 07:28 PM
Ramaswamy Vivek	10% Owner	Sep 03 '25	Sale	12.50	1,195,000	14,937,500	36,089,108	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 05 '25	Sale	12.96	385,816	5,000,175	35,508,359	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 04 '25	Sale	12.92	194,933	2,518,534	35,894,175	Sep 05 05:01 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Option Exercise	3.85	100,000	385,000	1,753,585	Aug 22 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Sale	11.72	100,000	1,172,000	1,653,585	Aug 22 09:00 PM
Venker Eric	Officer	Aug 20 '25	Proposed Sale	11.72	100,000	1,172,120		Aug 20 04:30 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jul 23 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Sale	11.52	100,000	1,152,000	1,462,223	Jul 23 09:00 PM
Venker Eric	Officer	Jul 21 '25	Proposed Sale	11.52	100,000	1,151,942		Jul 21 04:34 PM
Venker Eric	President & COO	Jun 20 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jun 24 09:01 PM
Venker Eric	President & COO	Jun 20 '25	Sale	11.45	100,000	1,145,000	1,462,223	Jun 24 09:01 PM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Sale	11.46	577,007	6,612,500	37,284,108	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Sale	11.45	565,266	6,472,296	37,861,115	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Proposed Sale	11.46	577,007	6,611,850		Jun 20 04:35 PM
Venker Eric	Officer	Jun 20 '25	Proposed Sale	11.45	100,000	1,145,268		Jun 20 04:13 PM

MP MP Materials Corporation daily Stock Chart

Peers: REE

| Held by: IJH VTI XME VB REMX VBK VXF MDY SPMD IWR

Index	-	P/E	-	EPS (ttm)	-0.70	Insider Own	19.31%	Shs Outstand	177.21M	Perf Week	2.17%
Market Cap	11.71B	Forward P/E	105.85	EPS next Y	0.62	Insider Trans	-3.27%	Shs Float	143.01M	Perf Month	23.74%
Enterprise Value	11.21B	PEG	-	EPS next Q	0.00	Inst Own	69.30%	Short Float	17.04%	Perf Quarter	0.74%
Income	-117.64M	P/S	50.30	EPS this Y	19.49%	Inst Trans	-7.19%	Short Ratio	2.59	Perf Half Y	9.61%
Sales	232.74M	P/B	5.96	EPS next Y	276.17%	ROA	-3.86%	Short Interest	24.37M	Perf YTD	30.75%
Book/sh	11.09	P/C	6.03	EPS next 5Y	-	ROE	-6.83%	52W High	100.25 -34.11%	Perf Year	206.94%
Cash/sh	10.95	P/FCF	-	EPS past 3/5Y	- -41.29%	ROIC	-3.52%	52W Low	18.64 254.36%	Perf 3Y	114.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.00% 22.66%	Gross Margin	-26.28%	Volatility	10.68% 7.31%	Perf 5Y	95.08%
Dividend TTM	-	EV/Sales	48.18	EPS Y/Y TTM	-95.87%	Oper. Margin	-68.60%	ATR (14)	4.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.51	Sales Y/Y TTM	26.44%	Profit Margin	-50.55%	RSI (14)	54.94	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	8.05	EPS Q/Q	-53.60%	SMA20	4.74%	Beta	1.63	Target Price	78.87
Payout	-	Debt/Eq	0.44	Sales Q/Q	-14.90%	SMA50	10.80%	Rel Volume	0.87	Prev Close	66.73
Employees	804	LT Debt/Eq	0.40	Earnings	Nov 06 AMC	SMA200	24.21%	Avg Volume	9.42M	Price	66.05
IPO	Jun 22, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.16% 0.59%	Trades		Volume	2,609,909	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Initiated	William Blair	Outperform
Dec-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$71
Nov-24-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$75
Nov-19-25	Initiated	Goldman	Buy	$77
Nov-14-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-10-25	Upgrade	Deutsche Bank	Hold → Buy	$71
Oct-09-25	Resumed	BMO Capital Markets	Market Perform	$76
Sep-23-25	Initiated	Daiwa Securities	Outperform	$80
Aug-01-25	Upgrade	Jefferies	Hold → Buy	$80
Jul-31-25	Resumed	Morgan Stanley	Equal-Weight	$65
Jul-07-25	Downgrade	Jefferies	Buy → Hold	$33
Jun-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$34
Sep-27-24	Reiterated	Robert W. Baird	Outperform	$20 → $25
Jul-15-24	Initiated	BMO Capital Markets	Market Perform	$16.50
Apr-23-24	Downgrade	JP Morgan	Overweight → Neutral	$20 → $16
Mar-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$26 → $15.50
Sep-06-23	Upgrade	Northland Capital	Market Perform → Outperform
Aug-31-23	Initiated	JP Morgan	Overweight	$27
Apr-18-23	Downgrade	Northland Capital	Outperform → Market Perform	$32
Jul-13-22	Initiated	Canaccord Genuity	Buy	$44

Show Previous Ratings

Today 04:25AM	Forget AI Stocks: This Materials Play Is Vital to the Tech Industry (Motley Fool)
Jan-27-26 04:35PM	USA Rare Earth Stock Price Target Triples Following Government Deal. Heres Why. (Barrons.com) +5.19%
10:05AM	As Trump Drops Tariff Threats on Greenland, Should You Buy This 1 Hot Rare Earths Stock? (Barchart)
09:09AM	USA Rare Earth Gets Huge Stock Price Target Boost Following Government Deal (Barrons.com)
08:04AM	Palantir and 5 More Stocks That Might Catch Trump's Attention-in a Good Way (Barrons.com)
07:52AM	Loading…
07:52AM	Rare Earth Stocks Backslide After Trump Takes Stake In USA Rare Earth (Investor's Business Daily)
07:03AM	Washington's $1.6B Endorsement Turns USA Rare Earth Into a Force (MarketBeat)
07:00AM	Trump Bolsters Critical Minerals Pipeline with $1.6 Billion Stake in USA Rare Earth (The Daily Upside)
05:03AM	MP Materials (MP) Drops 8.8% as Rival Gets Higher Funding From Govt (Insider Monkey)
01:00AM	Palantir and 5 More Stocks to Play Trumps Plan to Invest in America (Barrons.com)
Jan-26-26 04:32PM	Stocks Close Higher Ahead of Heavy Earnings Week and FOMC Meeting (Barchart) -8.82%
04:21PM	These Stocks Are Todays Movers: USA Rare Earth, CoreWeave, Micron, Intel, Newmont, Booz Allen, IonQ, and More (Barrons.com)
04:20PM	USA Rare Earth Is the Latest to Get Trump Deal. What It Means for the Stock. (Barrons.com)
03:03PM	Trump administration buys stake in USA Rare Earth as wave of government deals in critical minerals continues (Fortune)
02:31PM	Trump's Rare Earth Mega-Deal Sparks Rally In MP Materials And Peers (Benzinga)
01:26PM	Loading…
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
12:57PM	USA Rare Earth Rallies on Deal Talk. Why Trump's Mining Strategy Matters (GuruFocus.com)
12:56PM	USAR Jumps on Reported White House Investment Talks (GuruFocus.com)
12:48PM	What's Going On With MP Materials Stock Monday? (Benzinga)
12:37PM	USA Rare Earth Latest to Get Trump Deal. What It Means for the Stock. (Barrons.com)
12:19PM	3 Rare Earth Stocks to Watch Following Washington's Latest Trade Moves (MarketBeat)
11:41AM	Stocks See Support Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
10:44AM	Rare earth stocks jump as Trump administration takes stake in miner in $1.6 billion deal (Yahoo Finance)
10:18AM	Will USA Rare Earth Stock Run 100% Post-Trump? MP Materials Did (Benzinga)
10:03AM	USA Rare Earth Stock Surges on Megadeal. How Trump Is Boosting Rare-Earth Companies. (Barrons.com)
09:53AM	The White House is Now a Hedge Fund. 5 Government-Backed Stocks Wall Street is Watching. (Barchart)
09:50AM	Trump administration invests in another US rare earth miner to loosen China's grip on supply (Associated Press Finance)
09:44AM	Stocks to Watch Monday: CoreWeave, American Airlines, IonQ, Enphase (The Wall Street Journal)
09:28AM	Chinas Stranglehold on Critical Minerals Creates Massive Opportunity in These 5 Stocks (24/7 Wall St.)
08:36AM	Trump administration partners with another rare-earth company. Should you buy the stock? (MarketWatch)
07:57AM	Loading…
07:57AM	USA Rare Earth Stock Surges. How Trump Is Boosting Rare-Earth Companies. (Barrons.com)
06:01AM	Trump Admin To Acquire Stake In USA Rare Earth For $1.6 Billion: Report (Benzinga)
04:54AM	USAR Stock Surges 40%. How Trump Is Boosting Rare-Earth Companies. (Barrons.com)
Jan-25-26 10:05AM	This Overlooked Rare-Earth Stock Could Transform $1,000 Into Life-Changing Wealth (Motley Fool)
06:02AM	Trump Admin To Acquire Stake In USA Rare Earth For $1.6 Billion: Report (Benzinga)
Jan-24-26 09:37AM	Could Buying USA Rare Earth Stock Today Set You Up for Life? (Motley Fool)
Jan-23-26 01:36PM	Dow, S&P 500 Eye Weekly Losses Despite Tariff Threat Reversal (Schaeffer's Research)
Jan-22-26 12:25PM	Trump Vows 'Big Retaliation' as 'Sell America' List Grows (Barrons.com) +5.75%
12:19PM	Will USAR's Expansion Plan in France Boost ex-China Rare-Earth Supply Chains? (Zacks)
11:23AM	Market Movers: This is Why USA Rare Earth is up About 20% (24/7 Wall St.)
Jan-21-26 03:21PM	Lynas Seeks Pentagon Price-Floor Deal as Rare Earths Scrutiny Rises (GuruFocus.com) -5.45%
02:22PM	Atlantic Strategic Minerals Weighs Rare Earths Plant in Virginia (GuruFocus.com)
01:57PM	Stocks Rebound On Trump's Remarks, Natural Gas Rockets: What's Moving Markets Wednesday? (Benzinga)
11:51AM	Rare-Earth Stocks Get a Boost From Something New: Results. (Barrons.com)
06:01AM	These 7 Stocks Rallied More Than 200% Since Trump's Inauguration Day (Benzinga)
Jan-20-26 12:55PM	2 Rare Earth Stocks Hot Amid Greenland Gridlock (Schaeffer's Research)
11:18AM	These 7 Stocks Rallied More Than 200% Since Trump's Inauguration Day (Benzinga)
10:04AM	This Rare Earth Stock Caught an Upgrade. Its Helping. (Barrons.com)
07:37AM	This Rare Earth Stock Caught an Upgrade. It Isn't Helping. (Barrons.com)
Jan-19-26 12:35PM	Insiders Are Selling These 3 High-Flying Stocks (MarketBeat)
Jan-16-26 06:51PM	Will MP Materials Stock Have Room to Run in 2026?? (Motley Fool)
Jan-15-26 11:40AM	Trump, Congress Move On Rare Earths: 5 Stocks To Watch (Benzinga)
07:04AM	US lawmakers introduce bill to create $2.5 billion critical-minerals stockpile (Reuters)
07:02AM	Lawmakers propose $2.5B agency to boost production of rare earths and other critical minerals (Associated Press Finance)
05:30AM	Trumps Rare Earth Push Extends Lifeline to Green Tech (Bloomberg)
Jan-14-26 04:17PM	Greenland Technologies Stock Soars 24%. It Isnt That Greenland. (Barrons.com) +8.59%
03:46PM	3 ways to invest in what could become a $200 billion market for humanoid robots (MarketWatch)
01:25PM	Stocks Drop, Energy Sector Rises As Crude Eyes 6th Day Of Gains: What's Moving Markets Wednesday? (Benzinga)
11:06AM	Greenland Technologies Stock Soars. There Are Better Ways to Play the Geopolitical Tug-of-War. (Barrons.com)
Jan-13-26 04:58PM	L3 Harris Stock Rises. Its Building an Arsenal of Freedom With the U.S.and Launching an IPO. (Barrons.com)
11:13AM	Trump's War Department invests $1 billion to get pre-IPO shares of this rocket-motor maker (MarketWatch)
10:59AM	MP Materials Keeps Its Perfect Buy Rating After Defense Deal (Barrons.com)
09:08AM	L3 Harris Stock Soars. It's Building an 'Arsenal of Freedom' With the U.S.-and Launching an IPO. (Barrons.com)
08:00AM	L3 Harris to Build 'Arsenal of Freedom' With U.S., IPO Missile Business. Stock Soars. (Barrons.com)
Jan-12-26 01:41PM	Critical Metals' 100% Run Puts Rare Earth Stocks In Play For 2026's Top Trade (Benzinga) +5.39%
12:38PM	6 Strategic Stocks to Watch as Trump Tries to Buy Greenland (Barchart)
06:36AM	Trump Pushes Greenland Focus as Experts Question Rare Earth Mining Viability (GuruFocus.com)
06:31AM	Critical Metals Stock Surges Nearly 12% During Monday Pre-Market: What's Going On? (Benzinga)
Jan-11-26 01:06PM	MP Materials: Operational Success, Poor Capital Economics (GuruFocus.com)
07:05AM	Prediction: Industrial Stocks Could Take the Lead in the Next Market Cycle. Here's 1 to Watch. (Motley Fool)
Jan-10-26 12:41PM	President Trumps Stock Bets Have Crushed the Market. Should You Buy Them Now? (24/7 Wall St.)
08:32AM	Here's Why MP Materials Stock Slumped in December (And Why It's Surging in 2026) (Motley Fool)
Jan-09-26 10:34AM	This ETF Is Up 146% as the Battle Over Rare Earths Heats Up (MarketBeat)
08:13AM	Here's Why MP Materials Stock Rocketed Higher This Week (Motley Fool)
01:30AM	Oil Isn't the Only Commodity at Play in the U.S. Ouster of Maduro (Barrons.com)
Jan-08-26 09:08AM	Donald Trump Is Meddling in Markets. Its a Dangerous Line to Cross. (Barrons.com)
Jan-07-26 08:00PM	China Bans Rare Earths Exports To Japan Over Taiwan Spat (Oilprice.com)
Jan-06-26 08:41AM	Rare Earth Stocks Revive After China Slams Trump's Venezuela Intervention (Investor's Business Daily)
Jan-05-26 02:24PM	Why MP Materials Stock Is Up After Venezuela Military Action (Barrons.com) +6.64%
01:23PM	MP Materials Trades at Premium Value: Here's How to Play the Stock (Zacks)
11:20AM	Should You Invest $1,000 in MP Materials Right Now? (Motley Fool)
Dec-31-25 07:02AM	Will USAR's Arnold Partnership Strengthen Rare-Earth Supply Chains? (Zacks)
Dec-28-25 10:00AM	MP Materials Gained 230% in 2025. Should You Buy, Sell, or Hold MP Stock for 2026? (Barchart)
Dec-25-25 10:27AM	Is USA Rare Earth the Smartest Investment You Can Make Today? (Motley Fool)
Dec-24-25 05:48PM	Forget MP Materials: This Rare Earth Stock Is Up 21% in 2025 With More Upside Ahead (Motley Fool)
Dec-23-25 12:21PM	MP vs. UUUU: Which Rare Earth Stock Has an Edge Now? (Zacks)
09:29AM	MongoDB and Acadia Healthcare have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Dec-22-25 11:49AM	3 Rare Earth Stocks to Watch in 2026 as the Sector Heats Up (Zacks)
Dec-19-25 11:50AM	Is VanEck Rare Earth and Strategic Metals ETF the Smartest Investment You Can Make Today? (Motley Fool)
Dec-18-25 02:35PM	Is MP Materials Stock a Millionaire Maker? (Motley Fool)
Dec-17-25 08:55AM	Why This Government-Backed Stock Could Be the Biggest Winner of 2026 (InvestorPlace)
Dec-16-25 07:00PM	Large Critical Minerals Deposit Discovered In Utah (Oilprice.com)
08:55AM	Welcome to the Presidents Market (InvestorPlace)
Dec-15-25 10:49AM	MP Expects Return to Profitability in Q4: Achievable or Too Ambitious? (Zacks) -6.00%
09:00AM	Warner Bros. Is Blockbuster Finale to $4.5 Trillion M&A Haul (Bloomberg)
Dec-14-25 08:55AM	Robotics Is About to Become Americas Most Important Industry (InvestorPlace)
08:05AM	The Smartest Mining Stock to Buy With $100 Right Now (Motley Fool)
Dec-12-25 10:18AM	3 Growth Stocks to Buy and Hold for the Next Decade (Motley Fool) -5.58%
Dec-11-25 10:05AM	Is MP Stock a Buy, Hold or Sell After Its 98.9% Six-Month Rally? (Zacks)

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoops Elliot Dean	General Counsel and Secretary	Jan 20 '26	Sale	68.21	7,823	533,607	74,967	Jan 22 07:48 PM
Elliot Hoops	officer	Jan 20 '26	Proposed Sale	68.21	7,823	533,569		Jan 20 04:36 PM
Litinsky James H.	Chairman and CEO	Jan 08 '26	Sale	64.17	272,600	17,492,742	12,805,965	Jan 09 09:48 PM
Litinsky James H.	Chairman and CEO	Jan 07 '26	Sale	64.01	27,400	1,753,874	13,078,565	Jan 09 09:48 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Jan 08 '26	Proposed Sale	62.50	272,600	17,037,500		Jan 08 04:25 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Jan 07 '26	Proposed Sale	59.82	27,400	1,639,068		Jan 07 04:57 PM
Corbett Ryan	Chief Financial Officer	Dec 09 '25	Sale	60.00	38,146	2,288,760	156,666	Dec 10 09:11 PM
Corbett Ryan	Officer	Dec 09 '25	Proposed Sale	60.00	38,146	2,288,760		Dec 09 04:14 PM
Litinsky James H.	Chairman and CEO	Dec 05 '25	Sale	62.94	385,000	24,232,308	13,105,965	Dec 05 09:45 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Dec 05 '25	Proposed Sale	62.94	385,000	24,231,092		Dec 05 04:29 PM
Litinsky James H.	Chairman and CEO	Nov 20 '25	Sale	63.86	248,411	15,864,583	13,369,665	Nov 20 09:40 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 20 '25	Proposed Sale	63.86	248,411	15,864,147		Nov 20 04:23 PM
Corbett Ryan	Chief Financial Officer	Nov 17 '25	Sale	57.72	20,000	1,154,400	194,812	Nov 19 09:21 PM
Corbett Ryan	Officer	Nov 17 '25	Proposed Sale	57.72	20,000	1,154,480		Nov 17 01:13 PM
Rosenthal Michael Stuart	Chief Operating Officer	Aug 29 '25	Sale	72.02	150,000	10,802,838	1,284,409	Aug 29 09:23 PM
Rosenthal Michael Stuart	Officer	Aug 29 '25	Proposed Sale	72.02	150,000	10,803,255		Aug 29 04:20 PM
Hoops Elliot Dean	General Counsel and Secretary	Aug 01 '25	Sale	60.33	6,337	382,304	0	Aug 01 09:22 PM
Hoops Elliot Dean	Officer	Aug 01 '25	Proposed Sale	60.29	6,337	382,038		Aug 01 03:58 PM
Hoops Elliot Dean	General Counsel and Secretary	Jul 01 '25	Sale	31.94	6,338	202,464	6,337	Jul 03 09:27 PM
Hoops Elliot Dean	Officer	Jul 01 '25	Proposed Sale	31.90	6,338	202,209		Jul 01 04:36 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 26 '25	Sale	36.37	5,523	200,872	69,749	Jun 27 09:30 PM
Hoops Elliot Dean	Officer	Jun 26 '25	Proposed Sale	36.33	5,523	200,651		Jun 26 04:17 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 13 '25	Sale	29.96	5,538	165,918	12,675	Jun 13 09:25 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 12 '25	Sale	29.95	800	23,960	18,213	Jun 13 09:25 PM
Hoops Elliot Dean	Officer	Jun 13 '25	Proposed Sale	29.96	6,338	189,900		Jun 13 04:30 PM
Litinsky James H.	Chairman and CEO	Apr 14 '25	Sale	27.08	199,180	5,393,794	13,643,076	Apr 16 09:11 PM
Litinsky James H.	Chairman and CEO	Mar 25 '25	Sale	27.03	396,293	10,711,800	13,860,775	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 26 '25	Sale	27.00	18,519	500,013	13,842,256	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 20 '25	Sale	27.04	95,621	2,585,592	14,257,068	Mar 21 09:15 PM
Litinsky James H.	Chairman and CEO	Mar 18 '25	Sale	26.71	639,294	17,075,543	14,513,864	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 17 '25	Sale	26.77	489,918	13,115,105	15,153,158	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 19 '25	Sale	26.94	161,175	4,342,054	14,352,689	Mar 19 09:18 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 19 '25	Proposed Sale	26.83	788,356	21,151,591		Mar 19 05:04 PM
Corbett Ryan	Chief Financial Officer	Mar 14 '25	Sale	25.51	60,000	1,530,391	230,100	Mar 18 06:45 PM
Corbett Ryan	Chief Financial Officer	Mar 17 '25	Sale	27.00	15,000	405,000	214,812	Mar 18 06:45 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 18 '25	Proposed Sale	26.69	721,726	19,262,867		Mar 18 05:06 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 17 '25	Proposed Sale	26.83	489,918	13,144,500		Mar 17 05:05 PM
Corbett Ryan	Officer	Mar 17 '25	Proposed Sale	27.00	15,000	405,000		Mar 17 04:03 PM
Corbett Ryan	Officer	Mar 14 '25	Proposed Sale	25.00	60,000	1,500,000		Mar 14 04:09 PM
Litinsky James H.	Chairman and CEO	Feb 04 '25	Sale	24.01	386,223	9,273,214	15,643,076	Feb 06 09:13 PM

ROIV

Roivant Sciences Ltd

MP

MP Materials Corporation

Upgrade your FINVIZ experience